DMARD Taper-to-Discontinuation Approach Increases Flare Risk DMARD Taper-to-Discontinuation Approach Increases Flare Risk

In two trials, most patients with RA in remission who tapered csDMARD or TNF inhibitor drugs to withdrawal experienced flares within 3 years.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news